Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2/3 2Phase 1 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 8INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 4Pancreatic Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × titanium silicide × Clear all
NCT01285557 2024-09-19

DIGEST

Taiho Oncology, Inc.

Phase 3 Terminated
361 enrolled 18 charts
Gastrointestinal

Stomach Neoplasms

NCT00498225 2012-11-02

GEST

Taiho Pharmaceutical Co., Ltd.

Phase 3 Completed
834 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00150670 2011-07-07

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Taiho Pharmaceutical Co., Ltd.

Phase 3 Completed
300 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00152217 2011-07-07

Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)

Taiho Pharmaceutical Co., Ltd.

Phase 3 Completed
1,000 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00195572 2009-08-13

Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
200 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡